Academic Highlights: Optimizing Pharmacotherapy to Maximize Outcome in Schizophrenia
J Clin Psychiatry 2005;66(1):122-123
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Although abundant evidence shows that dysfunction in multiple neurotransmitter systems (including the serotonergic and the glutamatergic systems) contributes to the pathogenesis of schizophrenia, alterations in dopaminergrc systems are the best-documented neurochemical dysfunctions associated with this illness, according to Anissa Abi-Dargham, M.D. The modern dopamine hypothesis of schizophrenia proposes that positive symptoms of psychosis in patients with schizophrenia arise from a condition of up-regulated dopaminerglc neuronal activity in subcortical pathways, whereas negative symptoms and cognitive impairment result from a dopamine deficit in the cortical dopamine (DA) pathways.1,2 Traditional support for this hypothesis derives from the fact that typical antipsychotic agents, whose main property is the antagonism of D2 dopamine receptors, suppress positive symptoms but do not significantly improve and may even worsen negative symptoms.2